Mebias Discovery
Holds a game-changing platform exploiting protein-conformation dynamics to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
Active Portfolio Company
Holds a game-changing platform exploiting protein-conformation dynamics to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.
Active Portfolio Company